Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease

• DOI: 10.1111/jgh.16592
• Publication Date: 2024-05-10T06:33:54Z
• Authors: Yi‐Ting Chen; Tzu‐I Chen; Szu‐Ching Yin; Chia‐Wei Huang; Jee‐Fu Huang; Sheng‐Nan Lu; Ming‐Lun Yeh; Chung‐Feng Huang; Chia‐Yen Dai; Yu‐Wei Chen; Wan‐Long Chuang; Ming‐Lung Yu; Mei‐Hsuan Lee
• Keywords: Liver disease; Liver enzyme

Abstract Background and Aim This study estimated the prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) according to cardiometabolic risk factors. The long‐term impacts MASLD on all‐cause cardiometabolic‐specific mortality were evaluated. Methods We enrolled 343 816 adults aged ≥30 years who participated in a health screening program from 1997 through 2013. was identified basis abdominal ultrasonography profiles. participants further categorized by enzyme elevation. Baseline comorbidities classified self‐reported medication use clinical seromarkers. All‐cause deaths determined computerized data linkage with nationwide death certifications until December 31, 2020. Results overall 36.4%. Among patients MASLD, 35.9% had abnormal levels. Compared without enzymes positively associated ( P for trend < 0.001). After follow‐up, 9%–29% higher all‐cause, cardiovascular‐related, or diabetes‐related mortality. In groups elevated normal levels, multivariate‐adjusted hazard ratios cardiovascular 1.14 (1.05–1.25) 1.10 (1.03–1.17), respectively, those diabetes 1.42 (1.05–1.93) 1.24 (0.98–1.57), compared non‐MASLD group Discussion Individuals levels exhibited significantly risks should be monitored given consultation modifications.